Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Drug Development Services Market by Therapeutic Area (Neurology, Cardiovascular Diseases, Digestive System diseases, Oncology, Infectious and Immune System Diseases, Others), by Process (Lead Optimization, Candidate Validation, Target Selection, Target Validation, Hit-To-Lead Identification) and by Type (Biologic Drugs, Biology Services, Drug Metabolism and Pharmacokinetics, Medicinal Chemistry Services, Small Molecule Drugs): Global Opportunity Analysis and Industry Forecast, 2023-2032

A08431

Pages: NA

Charts: NA

Tables: NA

Drug development service is the proceeding of a new drug. Molecular manipulation, molecular designing, random screening, drug metabolites, and serendipity are the most common methods for drug discovery. Drug developmentreduces the costs and schedules for drug discovery. The methodof drug discovery is used in biotechnology, pharmacology, and medicine to discover and design new medications.Furthermore, drug development service is used to discover and formulate for the pharmaceutical, biotechnology and biopharmaceutical industries. This process involves various steps such as identification of applicants, synthesis, characterization, screening, and assays for therapeutic efficacy.Pharmaceutical drug development services are provided by CROs to pharmaceutical companies. The services include lead identification, drug discovery assistance, project management, clinical trials, and help in the development of drugs. The momentum spent on this market is accredited to the investments in developing drugs that can combat various diseases such as MS, HIV, and cancer.

Drug development servicesare mostly used in paternity testing, forensics, and anthropology with DNA analysis, and disaster victim identification is an important tool for this sector.

COVID-19 scenario analysis:

  • Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs, such as hydroxychloroquine, have witnessed a dramatic surge in demand for the management of COVID-19.
  • Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs as many developed countries are short of these drugs. The pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19.
  • Attributed to such factors, COVID-19 is expected to have a significant impact on the market.

Top impacting factors: Market scenario analysis, trends, drivers and impact analysis

Augmented demand and supply for medicines, technological upgrades, and upswing in the adoption of innovative techniques for discoveriesand increase in the number of patents’ expiry escalate the market growth globally. Increase in R&D activities, healthcare sector developments, rise in awareness among population about chronic diseases, rise in number of contract development, and manufacturers that stimulating drug discovery and rapidly build up the pharmaceutical industry are factors that encourage the growth of the drug development services market. Developing countries are expected to be at the center of this market.

On the other hand, high investment required as capital but low-profit marginsand strict regulations by Food and Drug Administration hamper the growth of the drug development services market. Moreover, healthcare system challenges in underdeveloped and developing countries impede the growth of the drug discovery services market.

New product launches to boost the market

InApril 2019, Charles River and CHDI Foundation Inc. collaborated on drug discovery and development. This collaboration is a five-year extension while they started working together in 2005 for Huntington’s disease.On10 September 2019, Laboratory Corporation (LabCorp) of America Holdings’s inaugurated the Covance Drug Development segment for R&D center in Shanghai, which is the largest in the Asia-Pacific region.Thermo Fisher Scientific introduced KaryoSat assays in stem cell research to accelerate research.On April 9, 2019, Eurofins Discovery announced a new drug discovery service,DiscoveryOne Integrated Drug Services.

Key benefits of the report:

  • This study presents the analytical depiction of the drug development services market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the drug development services market share.
  • The current market is quantitatively analyzed to highlight the drug development services market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the drug development services market research report:

  • Which are the leading market players active in the market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

 Key Market Segments

  • By Therapeutic Area
    • Neurology
    • Cardiovascular Diseases
    • Digestive System diseases
    • Oncology
    • Infectious and Immune System Diseases
    • Others
  • By Process
    • Lead Optimization
    • Candidate Validation
    • Target Selection
    • Target Validation
    • Hit-To-Lead Identification
  • By Type
    • Biologic Drugs
    • Biology Services
    • Drug Metabolism and Pharmacokinetics
    • Medicinal Chemistry Services
    • Small Molecule Drugs
  • By Region
    • North America
      • US
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • rest of Asia-Pacific
    • Latin America
      • Brazil
      • Mexico
      • rest of LATAM
    • Middle East
    • Africa

 
Key Market Players

  • Shanghai Medicilon
  • Eurofins Scientific
  • Albany Molecular Research Inc.
  • Aurigene Discovery Technologies Ltd.
  • TCG Lifesciences Pvt. Ltd.
  • Evotec SE
  • WuXi AppTec
  • Biotech Corporation
  • Selvita S. A.
  • Thermo Fisher Scientific, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DRUG DEVELOPMENT SERVICES MARKET, BY THERAPEUTIC AREA

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapeutic Area

    • 4.2. Neurology

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Cardiovascular Diseases

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Digestive System Diseases

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Oncology

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Infectious And Immune System Diseases

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Others

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: DRUG DEVELOPMENT SERVICES MARKET, BY PROCESS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Process

    • 5.2. Lead Optimization

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Candidate Validation

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Target Selection

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Target Validation

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Hit-To-Lead Identification

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: DRUG DEVELOPMENT SERVICES MARKET, BY TYPE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Type

    • 6.2. Biologic Drugs

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Biology Services

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Drug Metabolism And Pharmacokinetics

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Medicinal Chemistry Services

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Small Molecule Drugs

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: DRUG DEVELOPMENT SERVICES MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Therapeutic Area

      • 7.2.3. Market Size and Forecast, By Process

      • 7.2.4. Market Size and Forecast, By Type

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Drug Development Services Market

        • 7.2.6.1. Market Size and Forecast, By Therapeutic Area
        • 7.2.6.2. Market Size and Forecast, By Process
        • 7.2.6.3. Market Size and Forecast, By Type

      • 7.2.7. Canada Drug Development Services Market

        • 7.2.7.1. Market Size and Forecast, By Therapeutic Area
        • 7.2.7.2. Market Size and Forecast, By Process
        • 7.2.7.3. Market Size and Forecast, By Type

      • 7.2.8. Mexico Drug Development Services Market

        • 7.2.8.1. Market Size and Forecast, By Therapeutic Area
        • 7.2.8.2. Market Size and Forecast, By Process
        • 7.2.8.3. Market Size and Forecast, By Type

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Therapeutic Area

      • 7.3.3. Market Size and Forecast, By Process

      • 7.3.4. Market Size and Forecast, By Type

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Drug Development Services Market

        • 7.3.6.1. Market Size and Forecast, By Therapeutic Area
        • 7.3.6.2. Market Size and Forecast, By Process
        • 7.3.6.3. Market Size and Forecast, By Type

      • 7.3.7. Germany Drug Development Services Market

        • 7.3.7.1. Market Size and Forecast, By Therapeutic Area
        • 7.3.7.2. Market Size and Forecast, By Process
        • 7.3.7.3. Market Size and Forecast, By Type

      • 7.3.8. Italy Drug Development Services Market

        • 7.3.8.1. Market Size and Forecast, By Therapeutic Area
        • 7.3.8.2. Market Size and Forecast, By Process
        • 7.3.8.3. Market Size and Forecast, By Type

      • 7.3.9. Spain Drug Development Services Market

        • 7.3.9.1. Market Size and Forecast, By Therapeutic Area
        • 7.3.9.2. Market Size and Forecast, By Process
        • 7.3.9.3. Market Size and Forecast, By Type

      • 7.3.10. UK Drug Development Services Market

        • 7.3.10.1. Market Size and Forecast, By Therapeutic Area
        • 7.3.10.2. Market Size and Forecast, By Process
        • 7.3.10.3. Market Size and Forecast, By Type

      • 7.3.11. Russia Drug Development Services Market

        • 7.3.11.1. Market Size and Forecast, By Therapeutic Area
        • 7.3.11.2. Market Size and Forecast, By Process
        • 7.3.11.3. Market Size and Forecast, By Type

      • 7.3.12. Rest Of Europe Drug Development Services Market

        • 7.3.12.1. Market Size and Forecast, By Therapeutic Area
        • 7.3.12.2. Market Size and Forecast, By Process
        • 7.3.12.3. Market Size and Forecast, By Type

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Therapeutic Area

      • 7.4.3. Market Size and Forecast, By Process

      • 7.4.4. Market Size and Forecast, By Type

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Drug Development Services Market

        • 7.4.6.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.6.2. Market Size and Forecast, By Process
        • 7.4.6.3. Market Size and Forecast, By Type

      • 7.4.7. Japan Drug Development Services Market

        • 7.4.7.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.7.2. Market Size and Forecast, By Process
        • 7.4.7.3. Market Size and Forecast, By Type

      • 7.4.8. India Drug Development Services Market

        • 7.4.8.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.8.2. Market Size and Forecast, By Process
        • 7.4.8.3. Market Size and Forecast, By Type

      • 7.4.9. South Korea Drug Development Services Market

        • 7.4.9.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.9.2. Market Size and Forecast, By Process
        • 7.4.9.3. Market Size and Forecast, By Type

      • 7.4.10. Australia Drug Development Services Market

        • 7.4.10.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.10.2. Market Size and Forecast, By Process
        • 7.4.10.3. Market Size and Forecast, By Type

      • 7.4.11. Thailand Drug Development Services Market

        • 7.4.11.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.11.2. Market Size and Forecast, By Process
        • 7.4.11.3. Market Size and Forecast, By Type

      • 7.4.12. Malaysia Drug Development Services Market

        • 7.4.12.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.12.2. Market Size and Forecast, By Process
        • 7.4.12.3. Market Size and Forecast, By Type

      • 7.4.13. Indonesia Drug Development Services Market

        • 7.4.13.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.13.2. Market Size and Forecast, By Process
        • 7.4.13.3. Market Size and Forecast, By Type

      • 7.4.14. Rest of Asia Pacific Drug Development Services Market

        • 7.4.14.1. Market Size and Forecast, By Therapeutic Area
        • 7.4.14.2. Market Size and Forecast, By Process
        • 7.4.14.3. Market Size and Forecast, By Type

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Therapeutic Area

      • 7.5.3. Market Size and Forecast, By Process

      • 7.5.4. Market Size and Forecast, By Type

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Drug Development Services Market

        • 7.5.6.1. Market Size and Forecast, By Therapeutic Area
        • 7.5.6.2. Market Size and Forecast, By Process
        • 7.5.6.3. Market Size and Forecast, By Type

      • 7.5.7. South Africa Drug Development Services Market

        • 7.5.7.1. Market Size and Forecast, By Therapeutic Area
        • 7.5.7.2. Market Size and Forecast, By Process
        • 7.5.7.3. Market Size and Forecast, By Type

      • 7.5.8. Saudi Arabia Drug Development Services Market

        • 7.5.8.1. Market Size and Forecast, By Therapeutic Area
        • 7.5.8.2. Market Size and Forecast, By Process
        • 7.5.8.3. Market Size and Forecast, By Type

      • 7.5.9. UAE Drug Development Services Market

        • 7.5.9.1. Market Size and Forecast, By Therapeutic Area
        • 7.5.9.2. Market Size and Forecast, By Process
        • 7.5.9.3. Market Size and Forecast, By Type

      • 7.5.10. Argentina Drug Development Services Market

        • 7.5.10.1. Market Size and Forecast, By Therapeutic Area
        • 7.5.10.2. Market Size and Forecast, By Process
        • 7.5.10.3. Market Size and Forecast, By Type

      • 7.5.11. Rest of LAMEA Drug Development Services Market

        • 7.5.11.1. Market Size and Forecast, By Therapeutic Area
        • 7.5.11.2. Market Size and Forecast, By Process
        • 7.5.11.3. Market Size and Forecast, By Type

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Thermo Fisher Scientific, Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Shanghai Medicilon

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. TCG Lifesciences Pvt. Ltd.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Eurofins Scientific

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Biotech Corporation

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Aurigene Discovery Technologies Ltd.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Selvita S. A.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Albany Molecular Research Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. WuXi AppTec

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Evotec SE

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DEVELOPMENT SERVICES MARKET, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR NEUROLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR ONCOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DRUG DEVELOPMENT SERVICES MARKET, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL DRUG DEVELOPMENT SERVICES MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR BIOLOGY SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR DRUG METABOLISM AND PHARMACOKINETICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR MEDICINAL CHEMISTRY SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL DRUG DEVELOPMENT SERVICES MARKET FOR SMALL MOLECULE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA DRUG DEVELOPMENT SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. U.S. DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 26. U.S. DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 27. U.S. DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. CANADA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 29. CANADA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 30. CANADA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. MEXICO DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 32. MEXICO DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 33. MEXICO DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. EUROPE DRUG DEVELOPMENT SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 35. EUROPE DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 36. EUROPE DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 37. EUROPE DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. FRANCE DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 39. FRANCE DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 40. FRANCE DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 41. GERMANY DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 42. GERMANY DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 43. GERMANY DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. ITALY DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 45. ITALY DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 46. ITALY DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. SPAIN DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 48. SPAIN DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 49. SPAIN DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. UK DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 51. UK DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 52. UK DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. RUSSIA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 54. RUSSIA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 55. RUSSIA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. REST OF EUROPE DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 57. REST OF EUROPE DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 58. REST OF EUROPE DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. ASIA-PACIFIC DRUG DEVELOPMENT SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. ASIA-PACIFIC DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 61. ASIA-PACIFIC DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 62. ASIA-PACIFIC DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. CHINA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 64. CHINA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 65. CHINA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. JAPAN DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 67. JAPAN DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 68. JAPAN DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. INDIA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 70. INDIA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 71. INDIA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. SOUTH KOREA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 73. SOUTH KOREA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 74. SOUTH KOREA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 75. AUSTRALIA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 76. AUSTRALIA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 77. AUSTRALIA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 78. THAILAND DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 79. THAILAND DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 80. THAILAND DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 81. MALAYSIA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 82. MALAYSIA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 83. MALAYSIA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 84. INDONESIA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 85. INDONESIA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 86. INDONESIA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 88. REST OF ASIA PACIFIC DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 89. REST OF ASIA PACIFIC DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 90. LAMEA DRUG DEVELOPMENT SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 91. LAMEA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 92. LAMEA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 93. LAMEA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 94. BRAZIL DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 95. BRAZIL DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 96. BRAZIL DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 97. SOUTH AFRICA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 98. SOUTH AFRICA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 99. SOUTH AFRICA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 100. SAUDI ARABIA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 101. SAUDI ARABIA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 102. SAUDI ARABIA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 103. UAE DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 104. UAE DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 105. UAE DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 106. ARGENTINA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 107. ARGENTINA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 108. ARGENTINA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 109. REST OF LAMEA DRUG DEVELOPMENT SERVICES, BY THERAPEUTIC AREA, 2025-2033 ($MILLION)
  • TABLE 110. REST OF LAMEA DRUG DEVELOPMENT SERVICES, BY PROCESS, 2025-2033 ($MILLION)
  • TABLE 111. REST OF LAMEA DRUG DEVELOPMENT SERVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 112. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 113. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 114. THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 115. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 116. THERMO FISHER SCIENTIFIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. SHANGHAI MEDICILON: KEY EXECUTIVES
  • TABLE 118. SHANGHAI MEDICILON: COMPANY SNAPSHOT
  • TABLE 119. SHANGHAI MEDICILON: OPERATING SEGMENTS
  • TABLE 120. SHANGHAI MEDICILON: PRODUCT PORTFOLIO
  • TABLE 121. SHANGHAI MEDICILON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. TCG LIFESCIENCES PVT. LTD.: KEY EXECUTIVES
  • TABLE 123. TCG LIFESCIENCES PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 124. TCG LIFESCIENCES PVT. LTD.: OPERATING SEGMENTS
  • TABLE 125. TCG LIFESCIENCES PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 126. TCG LIFESCIENCES PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. EUROFINS SCIENTIFIC: KEY EXECUTIVES
  • TABLE 128. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 129. EUROFINS SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 130. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 131. EUROFINS SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. BIOTECH CORPORATION: KEY EXECUTIVES
  • TABLE 133. BIOTECH CORPORATION: COMPANY SNAPSHOT
  • TABLE 134. BIOTECH CORPORATION: OPERATING SEGMENTS
  • TABLE 135. BIOTECH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 136. BIOTECH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. AURIGENE DISCOVERY TECHNOLOGIES LTD.: KEY EXECUTIVES
  • TABLE 138. AURIGENE DISCOVERY TECHNOLOGIES LTD.: COMPANY SNAPSHOT
  • TABLE 139. AURIGENE DISCOVERY TECHNOLOGIES LTD.: OPERATING SEGMENTS
  • TABLE 140. AURIGENE DISCOVERY TECHNOLOGIES LTD.: PRODUCT PORTFOLIO
  • TABLE 141. AURIGENE DISCOVERY TECHNOLOGIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. SELVITA S. A.: KEY EXECUTIVES
  • TABLE 143. SELVITA S. A.: COMPANY SNAPSHOT
  • TABLE 144. SELVITA S. A.: OPERATING SEGMENTS
  • TABLE 145. SELVITA S. A.: PRODUCT PORTFOLIO
  • TABLE 146. SELVITA S. A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. ALBANY MOLECULAR RESEARCH INC.: KEY EXECUTIVES
  • TABLE 148. ALBANY MOLECULAR RESEARCH INC.: COMPANY SNAPSHOT
  • TABLE 149. ALBANY MOLECULAR RESEARCH INC.: OPERATING SEGMENTS
  • TABLE 150. ALBANY MOLECULAR RESEARCH INC.: PRODUCT PORTFOLIO
  • TABLE 151. ALBANY MOLECULAR RESEARCH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. WUXI APPTEC: KEY EXECUTIVES
  • TABLE 153. WUXI APPTEC: COMPANY SNAPSHOT
  • TABLE 154. WUXI APPTEC: OPERATING SEGMENTS
  • TABLE 155. WUXI APPTEC: PRODUCT PORTFOLIO
  • TABLE 156. WUXI APPTEC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. EVOTEC SE: KEY EXECUTIVES
  • TABLE 158. EVOTEC SE: COMPANY SNAPSHOT
  • TABLE 159. EVOTEC SE: OPERATING SEGMENTS
  • TABLE 160. EVOTEC SE: PRODUCT PORTFOLIO
  • TABLE 161. EVOTEC SE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DEVELOPMENT SERVICES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DRUG DEVELOPMENT SERVICES MARKET
  • FIGURE 3. SEGMENTATION DRUG DEVELOPMENT SERVICES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DRUG DEVELOPMENT SERVICES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDRUG DEVELOPMENT SERVICES MARKET
  • FIGURE 11. DRUG DEVELOPMENT SERVICES MARKET SEGMENTATION, BY BY THERAPEUTIC AREA
  • FIGURE 12. DRUG DEVELOPMENT SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DRUG DEVELOPMENT SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DRUG DEVELOPMENT SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. DRUG DEVELOPMENT SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. DRUG DEVELOPMENT SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DRUG DEVELOPMENT SERVICES MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. DRUG DEVELOPMENT SERVICES MARKET SEGMENTATION, BY BY PROCESS
  • FIGURE 19. DRUG DEVELOPMENT SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. DRUG DEVELOPMENT SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. DRUG DEVELOPMENT SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. DRUG DEVELOPMENT SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. DRUG DEVELOPMENT SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. DRUG DEVELOPMENT SERVICES MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 25. DRUG DEVELOPMENT SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. DRUG DEVELOPMENT SERVICES MARKET FOR BIOLOGY SERVICES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. DRUG DEVELOPMENT SERVICES MARKET FOR DRUG METABOLISM AND PHARMACOKINETICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. DRUG DEVELOPMENT SERVICES MARKET FOR MEDICINAL CHEMISTRY SERVICES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. DRUG DEVELOPMENT SERVICES MARKET FOR SMALL MOLECULE DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: DRUG DEVELOPMENT SERVICES MARKET
  • FIGURE 36. TOP PLAYER POSITIONING, 2024
  • FIGURE 37. THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. SHANGHAI MEDICILON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. SHANGHAI MEDICILON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. SHANGHAI MEDICILON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. TCG LIFESCIENCES PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. TCG LIFESCIENCES PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. TCG LIFESCIENCES PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. EUROFINS SCIENTIFIC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. EUROFINS SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. EUROFINS SCIENTIFIC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. BIOTECH CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. BIOTECH CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. BIOTECH CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. AURIGENE DISCOVERY TECHNOLOGIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. AURIGENE DISCOVERY TECHNOLOGIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. AURIGENE DISCOVERY TECHNOLOGIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. SELVITA S. A.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. SELVITA S. A.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. SELVITA S. A.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. ALBANY MOLECULAR RESEARCH INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. ALBANY MOLECULAR RESEARCH INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. ALBANY MOLECULAR RESEARCH INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 61. WUXI APPTEC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 62. WUXI APPTEC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 63. WUXI APPTEC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 64. EVOTEC SE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 65. EVOTEC SE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 66. EVOTEC SE: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Drug Development Services Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved